AVM Biotechnology, LLC, announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant. This $1.6 million award from the National Institute of Diabetes and Digestive Kidney Disease will allow the company to pursue additional research in the use of AVM0703 as a monotherapy and combination therapy to reverse recent onset and established Type 1 Diabetes.
[AVM Biotechnology, LLC (Business Wire)]
6445212
BBBBBBBB
items
1
apa
0
default
asc
1
173673
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/